Stock LXRX LEXICON PHARMACEUTICALS, INC.
Add to a list
To use this feature you must be a member
Log inSign up

Press Releases Lexicon Pharmaceuticals, Inc.

Equities

LXRX

US5288723027

Real-time Estimate Cboe BZX
Other stock markets
 07:48:21 29/04/2024 pm IST 		5-day change 1st Jan Change
1.605 USD +1.58% Intraday chart for Lexicon Pharmaceuticals, Inc. -7.12% +3.81%
22/04 Transcript : Lexicon Pharmaceuticals, Inc. - Analyst/Investor Day
25/03 Lexicon Pharmaceuticals Files Prospectus for Secondary Offering MT

Press Releases

Search
See the results
Unlock all the news on all businesses: Never miss an investment opportunity again!
100% Free Registration
Lonnel Coats Retires as Chief Executive Officer and Board Member of Lexicon Pharmaceuticals
AQ
Lexicon Pharmaceuticals to Host First Quarter 2024 Financial Results Conference Call and Webcast on May 2, 2024
AQ
Lexicon Pharmaceuticals to Host 2024 Investor Day
AQ
Lexicon Pharmaceuticals to Participate in the 23rd Annual Needham Virtual Healthcare Conference
AQ
Clinical Data on the Impact of Sotagliflozin on Stroke and Heart Attack Risk Among Four Lexicon-Sponsored Presentations at the American College of Cardiology 73rd Annual Scientific Session & Expo
AQ
New Post Hoc Analysis of inTandem3 Study Demonstrates Improvements In Glycemic Control With Sotagliflozin Treatment in Patients With Type 1 Diabetes and Chronic Kidney Disease
AQ
Lexicon: Q4 Earnings Snapshot
AQ
Lexicon Pharmaceuticals Reports Fourth Quarter 2023 Financial Results and Provides Business Update
AQ
Lexicon Announces Oversubscribed $250 Million Private Placement of Equity Securities
AQ
Lexicon Preparing to Resubmit Sotagliflozin NDA for Type 1 Diabetes Following Feedback From FDA
AQ
Lexicon Pharmaceuticals Provides Business and Pipeline Update at 42nd Annual J.P. Morgan Healthcare Conference
AQ
Lexicon Pharmaceuticals To Participate In The 42nd Annual JPMorgan Healthcare Conference
AQ
Lexicon Enrolls First Patient in Phase 2b Progress Study of LX9211 in Diabetic Peripheral Neuropathic Pain (DPNP)
AQ
Lexicon Pharmaceuticals to Participate in the 35th Annual Piper Sandler Healthcare Conference and the 6th Annual Evercore ISI HealthCONx Conference
AQ
INPEFA® (sotagliflozin) Use Associated With Early Clinical Benefit in Heart Failure and Atherosclerotic Events in Analysis of Clinical Data
AQ
Lexicon Pharmaceuticals to Participate in the Jefferies London Healthcare Conference
AQ
Lexicon: Q3 Earnings Snapshot
AQ
Lexicon Pharmaceuticals Reports Third Quarter 2023 Financial Results and Provides Business Update
AQ
Lexicon Pharmaceuticals to Host Third Quarter 2023 Financial Results Conference Call and Webcast on November 8, 2023
AQ
Data on Early Clinical Benefit for INPEFA® (Sotagliflozin) Will Be Among Five Lexicon-Sponsored Presentations at the American Heart Association Scientific Sessions 2023
AQ
No results for this search
All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Filters

Search

Announcement Date

Since

Until

  1. Stock Market
  2. Equities
  3. LXRX Stock
  4. News Lexicon Pharmaceuticals, Inc.
  5. Press Releases